- Home
- EVR vs BMRN Comparison
EVR vs BMRN Comparison
Compare EVR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVR
- BMRN
- Stock Information
- Founded
- EVR 1995
- BMRN 1996
- Country
- EVR United States
- BMRN United States
- Employees
- EVR N/A
- BMRN N/A
- Industry
- EVR Investment Managers
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- EVR Finance
- BMRN Health Care
- Exchange
- EVR Nasdaq
- BMRN Nasdaq
- Market Cap
- EVR 11.7B
- BMRN 10.5B
- IPO Year
- EVR 2006
- BMRN 1999
- Fundamental
- Price
- EVR $299.48
- BMRN $54.29
- Analyst Decision
- EVR Buy
- BMRN Buy
- Analyst Count
- EVR 9
- BMRN 19
- Target Price
- EVR $320.11
- BMRN $90.26
- AVG Volume (30 Days)
- EVR 414.5K
- BMRN 2.8M
- Earning Date
- EVR 10-29-2025
- BMRN 10-27-2025
- Dividend Yield
- EVR 1.13%
- BMRN N/A
- EPS Growth
- EVR 61.11
- BMRN 59.53
- EPS
- EVR 12.55
- BMRN 2.68
- Revenue
- EVR $3,542,875,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- EVR $24.72
- BMRN $13.32
- Revenue Next Year
- EVR $17.06
- BMRN $7.51
- P/E Ratio
- EVR $23.62
- BMRN $20.20
- Revenue Growth
- EVR 27.03
- BMRN 12.39
- 52 Week Low
- EVR $148.63
- BMRN $50.76
- 52 Week High
- EVR $364.42
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- EVR 43.43
- BMRN 53.35
- Support Level
- EVR $307.51
- BMRN $53.67
- Resistance Level
- EVR $324.28
- BMRN $55.34
- Average True Range (ATR)
- EVR 11.44
- BMRN 1.49
- MACD
- EVR 0.13
- BMRN 0.28
- Stochastic Oscillator
- EVR 33.28
- BMRN 78.60
About EVR Evercore Inc.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.